骨髓增生异常综合征患者重现性流式细胞术评分与修订版国际预后评分系统分层相关性

Correlation between the reproducible flow cytometric score and the International Prognostic Scoring System Revised in myelodysplastic syndromes

目的研究骨髓增生异常综合征（MDS）患者预后分层和重现性流式细胞术评分系统（FCM—score）相关性。方法采用FCM—score四参数[髓系前体细胞和有核细胞的比值（参数1）、B系前体细胞和CD34＋细胞的比值（参数2）、淋巴细胞和髓系前体细胞CD45平均荧光强度的比值（参数3）、粒细胞和淋巴细胞SSC峰值的比值（参数4）]对54例MDS患者进行评分，用修订版国际预后评分系统（IPSS．R）对MDS患者进行预后评估，并对FCM-score和各个阶段（由IPSS—R评估得到）的MDS进行相关性分析。结果FCM-score评分和IPSS—R分层之间存在正相关性（r=0．572，P〈0．05），FCM-score四参数中参数1和参数4与IPSS—R分层之间存在正相关性（P〈0．05）。结论FCM—score和IPSS．R分层存在相关性，可对MDS患者危险度进行初步评估。

Objective To study the correlation between the International Prognostic Scoring System Revised （IPSS-R） and the reproducibility of the flow cytometry score （FCM-score） in MDS patients. Methods Four parameters of the FCM-score [myeloblast-related cluster size （parameter 1）, B-progenitor-related cluster size （parameter 2）, ratio of the lymphocyte to myeloblast CD45 （parameter 3）, side scatter peak channel ratio of the granulocyte to lymphocyte （parameter 4）] were rated on 54 MDS patients. Prognostic value of IPSS-R was evaluated on clinical data from those MDS patients, and the correlation analysis of FCM-score and IPSS-R was carried out. Results There was a positive correlation between FCM-score and IPSS-R （r = 0.572, P 〈 0.05）. Besides, parameter 1 and parameter 4 of the FCM-score were positively associated with the IPSS-R （P 〈 0.05）. Conclusions FCM-score is associated with the IPSS-R. FCM-score maybe primarily evaluate the risk of MDS patients.